A Phase 4 interventional study of Esketamine 56 mg and Esketamine 84 mg in Depressive Disorder, Treatment-Resistant, sponsored by Janssen Research & Development, LLC. Completed at 54 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-25.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant — 4 open to participants now, 4 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Treatment-Resistant.
Among the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, this one is the 4th largest by enrollment, is the only one that started in 2020, is one of 4 in phase 4, and was the 11th registered.
448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →4 of the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant are open now, in 11 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, China, Japan and 1 more country
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–70
Dr. Inge Winter · Sites in Austria, Germany, Greece and 3 more countries
Ages 18–65
The George Institute · Sites in Australia
Ages 18+
By country, each count listing its studies:
Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 477 is above the median of 59 across 372 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 210 across the 18 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
21 studies in Depressive Disorder, Treatment-Resistant by Johnson & Johnson: 1 open now, 1 under way, 1 of them phase 3. Of 18 finished, 11 (61%) have results posted.
Among the 21 studies in Depressive Disorder, Treatment-Resistant by Johnson & Johnson, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2020, is one of 3 in phase 4, and was the 18th registered.
Johnson & Johnson’s Depressive Disorder, Treatment-Resistant studies by the year they started, since 2010.
1 of the studies testing esketamine in Depressive Disorder, Treatment-Resistant that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06278779The George InstituteComparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 21 in Depressive Disorder, Treatment-Resistant:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of each individual dose of esketamine nasal spray, 56 milligram (mg) and 84 mg, compared with placebo nasal spray in improving depressive symptoms in participants with treatment resistant depression (TRD), as assessed by the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from Day 1 (prerandomization) to the end of the 4 week double-blind treatment phase (Day 28).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive nasal spray treatment with esketamine 56 mg twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 Montgomery-Asberg Depression Rating Scale \[MADRS\] assessment).
Drug: Esketamine 56 mg
Participants will receive nasal spray treatment with esketamine 84 mg twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 MADRS assessment).
Drug: Esketamine 84 mg
Participants will receive nasal spray treatment with placebo twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 MADRS assessment).
Drug: Placebo
Esketamine 56 mg will be self administered as nasal spray.
Also known as: JNJ-54135419
Esketamine 84 mg will be self administered as nasal spray.
Also known as: JNJ-54135419
Matching placebo will be self administered as nasal spray.
Double-blind Treatment Phase: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Day 1 (Pre-randomization) to Day 28
The MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. The MADRS evaluated apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change in MADRS total score indicated improvement.
Time frame: Day 1 (pre-randomization) to Day 28 (end of DB treatment phase)
Double-blind Treatment Phase: Change in MADRS Total Score From Day 1 (Pre-randomization) to Day 2 (24 Hours Post First Dose on Day 1)
The MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. The MADRS evaluated apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change in MADRS total score indicated improvement.
Time frame: Day 1 (pre-randomization) to Day 2 of DB treatment phase (24 hours post first dose on Day 1)
Adult participants with recurrent or single (duration greater than or equal to \[\>=\] 2 years) episode major depressive disorder (DSM-5 criteria) without psychotic features who experienced inadequate response (less than or equal to \[\<=\] 25 percent \[%\] improvement) to \>=2 oral antidepressants during the current depressive episode were randomized in the study.
| Milestone | Placebo | Esketamine 56 mg | Esketamine 84 mg |
|---|---|---|---|
| Started | 250 | 106 | 121 |
| Treated | 250 | 105 | 121 |
| Completed | 238 | 101 | 107 |
| Not completed | 12 | 5 | 14 |
| Withdrew: Withdrawal by subject | 5 | 2 | 5 |
| Withdrew: Adverse event | 2 | 1 | 5 |
| Withdrew: Lack of efficacy | 2 | 0 | 2 |
| Withdrew: Protocol violation | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 1 |
| Withdrew: Randomized but not treated | 0 | 1 | 0 |
| Milestone | Placebo | Esketamine 56 mg | Esketamine 84 mg |
|---|---|---|---|
| Started | 237 | 99 | 106 |
| Participants who entered ol treatment phase | 237 | 99 | 105 |
| Participants who entered ol observation phase | 0 | 0 | 1 |
| Completed | 204 | 87 | 95 |
| Not completed | 33 | 12 | 11 |
| Withdrew: Withdrawal by subject | 8 | 5 | 6 |
| Withdrew: Lack of efficacy | 10 | 3 | 2 |
| Withdrew: Adverse event | 4 | 2 | 1 |
| Withdrew: Lost to follow-up | 4 | 1 | 2 |
| Withdrew: Protocol violation | 2 | 0 | 0 |
| Withdrew: Other | 5 | 1 | 0 |
The MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. The MADRS evaluated apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change in MADRS total score indicated improvement.
| Score on a scale | DB: Placebo | DB: Esketamine 56 mg | DB: Esketamine 84 mg |
|---|---|---|---|
| Double-blind Treatment Phase: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Day 1 (Pre-randomization) to Day 28 | -7.0 ± 10.07 | -12.7 ± 11.82 | -13.9 ± 11.89 |
The MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant treatment. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition. The MADRS evaluated apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change in MADRS total score indicated improvement.
| Score on a scale | DB: Placebo | DB: Esketamine 56 mg | DB: Esketamine 84 mg |
|---|---|---|---|
| Double-blind Treatment Phase: Change in MADRS Total Score From Day 1 (Pre-randomization) to Day 2 (24 Hours Post First Dose on Day 1) | -9.7 ± 10.27 | -13.9 ± 10.15 | -13.0 ± 9.68 |
Collected over Double-blind (DB) phase: From Day 1 (post-dose) to Day 28; Open-label (OL) phase: From Week 5 to Week 16; Follow-up (FU) phase: Up to 1 week after last dose of study drug in DB phase (Week 5) or OL treatment phase (Week 17). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB: Placebo | 0/250 (0%) | 3/250 (1.2%) | 73/250 (29.2%) |
| DB: Esketamine 56 mg | 0/106 (0%) | 1/105 (1%) | 69/105 (65.7%) |
| DB: Esketamine 84 mg | 0/121 (0%) | 2/121 (1.7%) | 80/121 (66.1%) |
| OL Treatment: Placebo to Esketamine | 0/237 (0%) | 6/237 (2.5%) | 147/237 (62%) |
| OL Treatment: Esketamine 56 mg to Esketamine | 0/99 (0%) | 3/99 (3%) | 49/99 (49.5%) |
| OL Treatment: Esketamine 84 mg to Esketamine | 0/105 (0%) | 0/105 (0%) | 44/105 (41.9%) |
| OL Observation Period | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Follow up: All Participants | 0/477 (0%) | 1/476 (0.2%) | 8/476 (1.7%) |
| Event | DB: Placebo | DB: Esketamine 56 mg | DB: Esketamine 84 mg | OL Treatment: Placebo to Esketamine | OL Treatment: Esketamine 56 mg to Esketamine | OL Treatment: Esketamine 84 mg to Esketamine | OL Observation Period | Follow up: All Participants |
|---|---|---|---|---|---|---|---|---|
| Abdominal Hernia ObstructiveGastrointestinal disorders | 0/250 | 0/105 | 0/121 | 0/237 | 1/99 | 0/105 | 0/1 | 0/476 |
| PeritonitisInfections and infestations | 0/250 | 0/105 | 0/121 | 0/237 | 1/99 | 0/105 | 0/1 | 0/476 |
| Endometrial CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/250 | 0/105 | 0/121 | 0/237 | 1/99 | 0/105 | 0/1 | 0/476 |
| Ankle FractureInjury, poisoning and procedural complications | 0/250 | 1/105 | 0/121 | 0/237 | 0/99 | 0/105 | 0/1 | 0/476 |
| Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/250 | 0/105 | 0/121 | 2/237 | 0/99 | 0/105 | 0/1 | 0/476 |
| Ophthalmic MigraineNervous system disorders | 0/250 | 0/105 | 1/121 | 0/237 | 0/99 | 0/105 | 0/1 | 0/476 |
| Suicide AttemptPsychiatric disorders | 0/250 | 0/105 | 1/121 | 0/237 | 0/99 | 0/105 | 0/1 | 0/476 |
| ConstipationGastrointestinal disorders | 0/250 | 0/105 | 0/121 | 1/237 | 0/99 | 0/105 | 0/1 | 0/476 |
| VomitingGastrointestinal disorders | 0/250 | 0/105 | 0/121 | 1/237 | 0/99 | 0/105 | 0/1 | 0/476 |
| Colon CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/250 | 0/105 | 0/121 | 1/237 | 0/99 | 0/105 | 0/1 | 0/476 |
| Event | DB: Placebo | DB: Esketamine 56 mg | DB: Esketamine 84 mg | OL Treatment: Placebo to Esketamine | OL Treatment: Esketamine 56 mg to Esketamine | OL Treatment: Esketamine 84 mg to Esketamine | OL Observation Period | Follow up: All Participants |
|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 21/250 | 24/105 | 32/121 | 69/237 | 18/99 | 15/105 | 0/1 | 0/476 |
| DissociationPsychiatric disorders | 7/250 | 23/105 | 32/121 | 42/237 | 12/99 | 15/105 | 0/1 | 0/476 |
| DizzinessNervous system disorders | 18/250 | 22/105 | 27/121 | 45/237 | 8/99 | 10/105 | 0/1 | 1/476 |
| HeadacheNervous system disorders | 22/250 | 19/105 | 24/121 | 36/237 | 13/99 | 11/105 | 0/1 | 2/476 |
| VomitingGastrointestinal disorders | 1/250 | 5/105 | 10/121 | 27/237 | 6/99 | 2/105 | 0/1 | 1/476 |
| AnxietyPsychiatric disorders | 3/250 | 5/105 | 10/121 | 14/237 | 3/99 | 4/105 | 0/1 | 0/476 |
| FatigueGeneral disorders | 11/250 | 8/105 | 7/121 | 18/237 | 6/99 | 5/105 | 0/1 | 0/476 |
| Feeling DrunkGeneral disorders | 2/250 | 8/105 | 8/121 | 13/237 | 6/99 | 6/105 | 0/1 | 0/476 |
| DiarrhoeaGastrointestinal disorders | 6/250 | 3/105 | 1/121 | 16/237 | 5/99 | 3/105 | 0/1 | 1/476 |
| HypoaesthesiaNervous system disorders | 1/250 | 2/105 | 5/121 | 15/237 | 2/99 | 4/105 | 0/1 | 0/476 |
Safety analysis set included all randomized participants (participants who met and did not meet nonresponse criteria) who received at least 1 dose of DB study intervention.
| Age, Categorical(Participants) | Placebo | Esketamine 56 mg | Esketamine 84 mg | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 229 | 95 | 107 | 431 |
| >=65 years | 21 | 10 | 14 | 45 |
| Age, Continuous(Years) | Placebo | Esketamine 56 mg | Esketamine 84 mg | Total |
|---|---|---|---|---|
| Mean | 45.4 ± 13.72 | 45.1 ± 13.92 | 45.1 ± 14.75 | 45.3 ± 14.01 |
| Sex: Female, Male(Participants) | Placebo | Esketamine 56 mg | Esketamine 84 mg | Total |
|---|---|---|---|---|
| Female | 147 | 60 | 77 | 284 |
| Male | 103 | 45 | 44 | 192 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Esketamine 56 mg | Esketamine 84 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 25 | 9 | 8 | 42 |
| Not Hispanic or Latino | 221 | 95 | 112 | 428 |
| Unknown or Not Reported | 4 | 1 | 1 | 6 |
| Race (NIH/OMB)(Participants) | Placebo | Esketamine 56 mg | Esketamine 84 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 6 | 3 | 5 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 | 2 |
| Black or African American | 17 | 7 | 11 | 35 |
| White | 217 | 91 | 102 | 410 |
| More than one race | 6 | 1 | 2 | 9 |
| Unknown or Not Reported | 4 | 1 | 0 | 5 |
| Region of Enrollment(Participants) | Placebo | Esketamine 56 mg | Esketamine 84 mg | Total |
|---|---|---|---|---|
| United States | 250 | 105 | 121 | 476 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2020 to primary completion in Jan 2024, 38 months.
Results were first posted in Mar 2025, 1 year 1 month after primary completion.
Of 18 phase 4 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 59. This study's 38 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esketamine
Depressive Disorder, Treatment-Resistant →
Janssen Research & Development, LLC →